Novo Nordisk A/S - Reduction of the share capital
(Thomson Reuters ONE) -
Bagsværd, Denmark, 21 April 2017 - At Novo Nordisk's Annual General Meeting on
23 March 2017, it was decided to reduce the company's B share capital from DKK
402,512,800 to DKK 392,512,800 by cancellation of part of the company's
portfolio of own B shares at a nominal value of DKK 10,000,000 divided into
50,000,000 B shares of DKK 0.20 each.
Today, Novo Nordisk has registered the implementation of the reduction of the
share capital with the Danish Business Authority and cancelled nominally DKK
10,000,000 B shares. After the reduction of the share capital, the company's
share capital is nominally DKK 500,000,000, which is divided into an A share
capital of nominally DKK 107,487,200 and a B share capital of nominally DKK
392,512,800.
The reduction in the share capital will not affect Novo Nordisk's share
repurchase programme which will continue as previously announced.
Further information
Media:
Anne Margrethe Hauge +45 3079 3450 amhg(at)novonordisk.com
Investors:
Peter Hugreffe Ankersen +45 3075 9085 phak(at)novonordisk.com
Hanna Ögren +45 3079 8519 haoe(at)novonordisk.com
Anders Mikkelsen +45 3079 4461 armk(at)novonordisk.com
Kasper Veje (US) +1 609 235 8567 kpvj(at)novonordisk.com
Company announcement No 29 / 2017
CA170421_Kapitalnedsættelse_UK:
http://hugin.info/2013/R/2097772/794349.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 21.04.2017 - 16:29 Uhr
Sprache: Deutsch
News-ID 537617
Anzahl Zeichen: 1977
contact information:
Town:
Bagsvaerd
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 196 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novo Nordisk A/S - Reduction of the share capital"
steht unter der journalistisch-redaktionellen Verantwortung von
Novo Nordisk A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
